Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.49 |
| ▸ | TUBB | P07437 | 6/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15841293 | 0.90 | LMNA (1.00) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL29432464 | 0.90 | LMNA (1.00) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL11366152 | 0.87 | LMNA (0.62) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL20909217 | 0.86 | LMNA (0.60) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL11379892 | 0.84 | LMNA (0.60) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL11388806 | 0.84 | LMNA (0.59) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL30704747 | 0.82 | LMNA (0.57) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL10816027 | 0.82 | LMNA (0.57) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL24359625 | 0.81 | LMNA (0.67) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL10742639 | 0.81 | LMNA (0.56) | LMNACYP1A2HIF1ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| WO-2012112956-A2 | COMPOUNDS AND METHODS FOR TARGETING LEUKEMIC STEM CELLS | THE BROAD INSTITUTE, INC (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112958-A2 | HIGH-THROUGHPUT ASSAYS TO PROBE LEUKEMIA WITHIN THE STROMAL NICHE | THE BROAD INSTITUTE, INC (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | LMNA 1828/4885CYP1A2 4782/4885HIF1A 709/4885 |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | LMNA 1828/4885CYP1A2 4782/4885HIF1A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.